Literature DB >> 23166215

eComment. Should persistent N2/N3 non-small cell lung cancer be treated by surgery?

Alessandro Baisi1, Federico Raveglia, Matilde De Simone, Ugo Cioffi.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23166215      PMCID： PMC3501326          DOI： 10.1093/icvts/ivs477

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN： 1569-9285


× No keyword cloud information.
  5 in total

1.  Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?

Authors:  Volker Steger; Tobias Walker; Migdat Mustafi; Karoline Lehrach; Thomas Kyriss; Stefanie Veit; Godehard Friedel; Thorsten Walles
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-20

Review 2.  Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures.

Authors:  Sergi Call; Ramon Rami-Porta; Carme Obiols; Mireia Serra-Mitjans; Guadalupe Gonzalez-Pont; Romà Bastús-Piulats; Salvador Quintana; Jose Belda-Sanchis
Journal:  Eur J Cardiothorac Surg       Date:  2010-11-26       Impact factor: 4.191

3.  Sleeve lobectomy after induction chemoradiotherapy.

Authors:  Abel Gómez-Caro; Marc Boada; Noemí Reguart; Nuria Viñolas; Frances Casas; Laureano Molins
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-04       Impact factor: 4.191

4.  Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Lary A Robinson; John C Ruckdeschel; Henry Wagner; Craig W Stevens
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

5.  Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.

Authors:  Christophe Dooms; Eric Verbeken; Sigrid Stroobants; Kris Nackaerts; Paul De Leyn; Johan Vansteenkiste
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.